Journal article icon

Journal article

Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?

Abstract:

BACKGROUND: Somatostatin analogs (SA) have been used for over 25 years in the treatment of acromegaly. A major disadvantage is the need to continue therapy indefinitely. OBJECTIVE: To evaluate the feasibility of discontinuing therapy in well-controlled patients with acromegaly treated chronically with SA. DESIGN AND METHODS: Of the 205 subjects on octreotide LAR, we selected those who met the following criteria: two or more years of treatment, a stable dose and injection interval of 20  mg e...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1530/eje-11-0738

Authors


Ramírez, C More by this author
González, B More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, OCDEM
Rábago, J More by this author
Expand authors...
Journal:
European journal of endocrinology / European Federation of Endocrine Societies
Volume:
166
Issue:
1
Pages:
21-26
Publication date:
2012-01-05
DOI:
EISSN:
1479-683X
ISSN:
0804-4643
URN:
uuid:e91e54bb-68ac-4569-91a6-616f5b03f5e4
Source identifiers:
221322
Local pid:
pubs:221322

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP